Endo (ENDP) Has No Linden Care Exposure - RBC Capital

RBC Capital analyst Randall Stanicky said Endo International plc (NASDAQ: ENDP) has no Linden Care exposure. The firm retained a Top Pick rating and price target of $91.00.

"We have confirmed with ENDP that it has zero exposure while DEPO has informed us it has 1/2% revenue exposure to ESRX linked scripts through Linden Care, spread equally across ‎Gralise, Cambia and Lazanda.‎ Per our separate note, we believe the INSY exposure to ESRX scripts through Linden Care is about 1% of revenue."

For an analyst ratings summary and ratings history on Endo International plc click here. For more ratings news on Endo International plc click here.

Shares of Endo International plc closed at $55.57 yesterday.

You May Also Be Interested In

• DA Davidson Reiterates Buy Rating on Tractor Supply Company (TSCO) Amid Soft Q2 Expectations
• Hut 8 Mining Corp. (HUT) PT Raised to $145 at Needham
• Better Home & Finance Holding (BETR) PT Lowered to $32 at Cantor Fitzgerald on Near-Term Pressures